Neu2000, promising neuroprotectant to treat ischemic stroke

Published: 2010-12-14 06:56:00

Updated: 2010-12-14 06:56:00

Neu2000 remains the primary focus of the drug’s development. Neu2000’s strong anti-oxidation activity, its potent NMDA antagonist activity, and its anti-zinc protective activity make it a promising neuroprotectant to treat ischemic stroke, according to Neurotech Pharmaceuticals, a local biopharma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK